All articles tagged with #vesper 3
Mid-stage data from Pfizer’s obesity drug berobenatide (from Metsera) suggest dosing it monthly after an initial weekly period can sustain weight loss through 28 weeks, with up to 12.1% loss in patients who stayed on treatment, though the monthly pace lags Lilly’s Zepbound and competitive clarity remains uncertain.
Pfizer presented midstage results for berobenatide, a monthly GLP-1 obesity drug acquired with Metsera for $10 billion, showing a side-effect profile similar to Novo Nordisk’s Wegovy (average nausea ~38%, vomiting ~23%). The long half-life makes monthly dosing front-loaded, and researchers plan a slower dose ramp in late-stage trials. Weight loss reached up to 12.3% in non-diabetics; analysts expect 20–25% vomiting and see monthly dosing as a potential differentiator from weekly rivals like Wegovy and Lilly’s Zepbound.